RBR-758cbn
Not yet recruiting
Phase 1
A phase I/II single center, open-label study to evaluate the safety, tolerability, pharmacodynamics and preliminary efficacy of intracisternal RGX-111 gene therapy in subjects with severe mucopolysaccharidosis type I
Hospitais de Clínicas de Porto Alegre0 sitesJune 25, 2018
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Mucopolysaccharidosis type I
- Sponsor
- Hospitais de Clínicas de Porto Alegre
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A male or female less than 3 years of age; The subject’s legal guardian(s) is(are) willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research\-related procedures; Has a documented diagnosis of severe Mucopolysaccharidosis Type I (MPS I) \-Hurler confirmed by homozygosity or compound heterozygosity for mutations exclusively associated with the severe phenotype; Has an intelligent quotient (IQ) score of greater than or equal to 55; Has sufficient auditory and visual capacity, with or without aids, to complete the required protocol testing and willing to be compliant with wearing the aid, if applicable, on testing days
Exclusion Criteria
- •Has a contraindication for an intracisternal injection (IC); Has any neurocognitive deficit not attributable to Mucopolysaccharidosis Type I (MPS I) or has a diagnosis of a neuropsychiatric condition that may, in the opinion of the PI, confound interpretation of study results; Has any contraindication to lumbar puncture; Has undergone hematopoetic stem cell transplantation (HSCT); Has had prior treatment with an Adeno\-associated virus (AAV)\-based gene therapy product; Has received intrathecal (IT) laronidase at any time and experienced a significant Adverse event (AE) considered related to IT administration that, in the opinion of the PI, would put the subject at undue risk; Has a platelet count less than 100,000 per
- •microliter; Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 × upper limit of normal (ULN) or total bilirubin greater than 1\.5 × ULN at screening, unless the subject has a previously known history of Gilbert’s syndrome; Has a history of human immunodeficiency virus (HIV) or hepatitis B or hepatitis C virus infection, or positive screening tests for hepatitis B surface antigen or hepatitis B core antibody, or hepatitis C or HIV antibodies
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Prospective trials to evaluate the safety of Allogeneic bone marrow derived mesenchymal stem cell in patients with Chronic Kidney DiseaseDiseases of the genitourinary systemKCT0006783Asan Medical Center10
Recruiting
Not Applicable
A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)Advanced solid tumors known to overexpress GRPRAdvanced solid tumorsgastrin-releasing peptide receptor10027655NL-OMON54819Advanced Accelerator Applications International SA10
Active, not recruiting
Phase 1/2
NeoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake.2023-507170-41-00Advanced Accelerator Applications International S.A., Advanced Accelerator Applications International S.A.9
Active, not recruiting
Phase 1
eoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake.Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptakeTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004727-37-GBAdvanced Accelerator Applications International SA71
Recruiting
Phase 1
eoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake.CTIS2023-507170-41-00Advanced Accelerator Applications International S.A.51